Moderna (MRNA) EBITDA Margin (2017 - 2026)
Moderna (MRNA) posted quarterly EBITDA Margin of 562.07% for Q2 2026, up 7666.0% year-over-year from 7.24% in Q2 2025, and down 57.53% on a QoQ basis from 356.81% in Q1 2026.
Moderna (MRNA) EBITDA Margin (2017 - 2026) Analysis & Trends
Moderna has reported EBITDA Margin for 10 years, with the latest figure at 562.07% in Q2 2026.
- EBITDA Margin for Q2 2026 came in at 562.07%, up 7666.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 149.01% (down 4268.0% YoY), and the FY2025 annual result was 158.13%, down 3622.0% from the prior year.
- EBITDA Margin declined to 562.07% in Q2 2026, from 356.81% in the prior quarter.
- Over five years, EBITDA Margin peaked at 69.68% in Q1 2022 and troughed at 972.22% in Q1 2025.
- A 5-year average of 256.85% and a median of 118.14% in 2023 frame the typical range for EBITDA Margin.
- The widest annual swing landed in 2024, when EBITDA Margin tumbled 73843 bps; it then surged 61541 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 31.08% in 2022, then plunged by 99 bps to 0.21% in 2023, then plunged by 60530 bps to 128.99% in 2024, then grew by 2 bps to 126.4% in 2025, then sank by 345 bps to 562.07% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 562.07% in Q2 2026, 356.81% in Q1 2026, and 126.4% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 19.75% |
| 10 | Roivant Sciences | 26.29 Bn | 26.29 Bn | 1.16 Mn | -25,380.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -562.07% |
| Mar 31, 2026 | -356.81% |
| Dec 31, 2025 | -126.40% |
| Sep 30, 2025 | -25.59% |
| Jun 30, 2025 | -638.73% |
| Mar 31, 2025 | -972.22% |
| Dec 31, 2024 | -128.99% |
| Sep 30, 2024 | -3.76% |
| Jun 30, 2024 | -565.56% |
| Mar 31, 2024 | -758.08% |
| Dec 31, 2023 | 0.21% |
| Sep 30, 2023 | -109.89% |
| Jun 30, 2023 | -542.73% |
| Mar 31, 2023 | -19.66% |
| Dec 31, 2022 | 31.08% |
| Sep 30, 2022 | 34.66% |
| Jun 30, 2022 | 51.53% |
| Mar 31, 2022 | 69.68% |
| Dec 31, 2021 | 75.02% |
| Sep 30, 2021 | 71.60% |